Sawai Group Holdings Co., Ltd.
Stock Price Chart
2026/04/15 UpdatedPrice Trend
2026/04/15 UpdatedPrice & Trading Details
2026/04/15 UpdatedPRICE
TRADING
Analyst Recommendations 9 analysts
Updated 2026/04/01Shareholder Composition
Updated 2026/04/01Major Holders
Updated 2026/04/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.
|
2.8M | 0.00% | |
|
Artisan Partners Funds Inc.-Artisan International Small-Mid Fund
|
1.7M | -10.27% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
1.5M | +3.97% | |
|
Victory Portfolios-Victory Trivalent International Small-Cap Fund
|
998.7K | -3.03% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
985.1K | +2.49% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
735.9K | +1.04% |
Dividend History
Updated 2026/04/12| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥28 | -48.1% |
| 2025 | ¥54 | +13.3% |
| 2024 | ¥48 | +10.0% |
| 2023 | ¥43 | 0.0% |
| 2022 | ¥43 | - |
Financial Performance
2026/04/12 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥193,816M | ¥163,702M | ¥176,862M | ¥189,024M |
| Gross Profit | ¥66,652M | ¥50,252M | ¥54,319M | ¥56,352M |
| Operating Income | -¥35,888M | ¥16,054M | ¥18,619M | ¥20,808M |
| Pretax Income | -¥35,743M | ¥16,248M | ¥18,820M | ¥20,958M |
| Net Income | -¥28,269M | ¥12,667M | ¥13,695M | ¥22,938M |
| EPS | -¥215.18 | ¥96.20 | ¥103.93 | ¥184.45 |
| Operating Margin | -18.52% | 9.81% | 10.53% | 11.01% |
| Balance Sheet | ||||
| Total Assets | ¥349,502M | ¥364,165M | ¥382,024M | ¥354,623M |
| Total Equity | ¥190,067M | ¥201,643M | ¥212,662M | ¥173,854M |
| Total Liabilities | ¥159,435M | ¥162,522M | ¥169,362M | ¥180,769M |
| Cash | ¥47,717M | ¥33,076M | ¥26,368M | ¥38,785M |
| Interest-bearing Debt | ¥66,749M | ¥73,132M | ¥82,890M | ¥91,339M |
| Equity Ratio | 54.38% | 55.37% | 55.67% | 49.03% |
| D/E Ratio | 0.35 | 0.36 | 0.39 | 0.53 |
| Cash Flow | ||||
| Operating CF | ¥34,310M | ¥13,026M | ¥23,149M | ¥27,851M |
| Investing CF | -¥30,395M | -¥27,134M | -¥23,112M | ¥6,480M |
| Financing CF | -¥11,262M | -¥1,267M | ¥2,363M | -¥32,704M |
| Free CF | ¥10,966M | -¥14,115M | -¥1,500M | ¥337M |
| Efficiency | ||||
| ROE | -14.87% | 6.28% | 6.44% | 13.19% |
| ROA | -8.09% | 3.48% | 3.58% | 6.47% |
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥2,667
Rating Score: 1.89 (Based on 9 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacture, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and anus, chemotherapeutic and antineoplastic agents, respiratory system, etc., as well as vitamin preparations. It sells its generic drugs through distributors, wholesalers, and retailers in Japan and the United States. The company was founded in 1929 and is headquartered in Osaka, Japan.
